The global bleeding disorders treatment market reached a valuation of US$ 12.7 Bn in 2020, and this industry is expected to rise at a high CAGR of 6.7% to reach US$ 19.9 Bn by the end of 2027.
The hemophilia A disease segment is projected to increase at 6.6% CAGR from 2021 to 2027. Rising awareness about the effectiveness of hemophilia A medicines is driving complementing market growth.
Increasing Global Awareness of Bleeding Disorders
Bleeding disorders are a group of medical conditions that affect the body’s ability to form blood clots, leading to excessive bleeding. These disorders can be inherited or acquired and can range from mild to severe. Examples of bleeding disorders include hemophilia, von Willebrand disease, and platelet function disorders.
Despite being rare, bleeding disorders can have a significant impact on an individual’s quality of life. The symptoms of these disorders can include spontaneous bleeding, prolonged bleeding after injury or surgery, and easy bruising. The treatment for bleeding disorders varies depending on the type and severity of the disorder but can include medication, blood transfusions, and surgery. Over the years, there has been a growing awareness of bleeding disorders across the world. This is due in part to increased education and outreach efforts by healthcare professionals and patient advocacy groups. In addition, advancements in medical technology have made it easier to diagnose and treat bleeding disorders.
However, there is still much work to be done in terms of raising awareness of these disorders. Many people with bleeding disorders go undiagnosed, and even those who are diagnosed may not receive the appropriate treatment and support. It is crucial that individuals with bleeding disorders receive timely and accurate diagnoses and have access to the necessary treatment and resources. Overall, the growing awareness of bleeding disorders is a positive step towards improving the lives of those affected by these conditions. By continuing to educate and advocate for individuals with bleeding disorders, we can work towards a future where these conditions are better understood, diagnosed, and treated.
The blood disorders treatment market is competitive and fragmented, with a number of prominent companies operating in this space. In terms of market share, the industry is currently dominated by a few significant competitors.
- In November 2020, Pfizer announced the start of the Phase III BASIS study of marstacimab, an experimental treatment for treating persons with severe hemophilia A or B. The U.S. Food and Drug Administration (FDA) granted it fast track status for use in combination with inhibitors as a potential treatment for hemophilia A and B.
Key Companies Profiled
- Bayer AG
- CSL Behring
- Grifols International SA
- Novo Nordisk A/S
- Octapharma AG
- Pfizer, Inc.